52805-37-5

Basic information

• Product Name: 3-(Benzyloxy)-4-Methoxybenzonitrile
• Synonyms: 3-(Benzyloxy)-4-Methoxybenzonitrile;3-(Benzyloxy)-4-methoxybenzonitrile >97%
• CAS NO: 52805-37-5
• Molecular Formula: C₁₅H₁₃NO₂
• Molecular Weight: 239.26922
• Mol File: 52805-37-5.mol
• Article Data: 13

Chemical Properties

• Melting Point: 73-74 °C(Solv: ethyl acetate (141-78-6); hexane (110-54-3))
• Boiling Point: 386.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(Benzyloxy)-4-Methoxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Benzyloxy)-4-Methoxybenzonitrile(52805-37-5)
• EPA Substance Registry System: 3-(Benzyloxy)-4-Methoxybenzonitrile(52805-37-5)

Safety Data

• Hazardous Substances Data: 52805-37-5(Hazardous Substances Data)

Usage

General Description

3-(Benzyloxy)-4-Methoxybenzonitrile, also known as 4-Methoxy-3-(phenylmethoxy)benzonitrile, is a chemical compound with the molecular formula C15H13NO2. It is a white to light yellow crystalline powder with a molecular weight of 239.27 g/mol. 3-(Benzyloxy)-4-Methoxybenzonitrile is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds, as well as in research and development. It is a versatile building block in organic chemistry due to its functional groups, such as the benzyloxy and methoxy groups, which allow for further modification and derivatization. Additionally, 3-(Benzyloxy)-4-Methoxybenzonitrile has been investigated for its potential biological activity, particularly as an antitumor and antifungal agent.

Upstream product

• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 97798-37-3 3-Benzyloxy-4-methoxybenzoyl cyanide 
• 55667-17-9 3-benzyloxy-4-methoxybenzaldehyde oxime 
• 67387-77-3 (3-Benzyloxy-4-methoxy-phenyl)-hydroxy-acetonitrile 
• 247570-05-4 3-benzyloxy-4-methoxybenzamide 
• 52805-46-6 2-methoxy-5-cyanophenol 
• 100-39-0 benzyl bromide 
• 621-59-0 isovanillin 

Downstream Products

• 52805-46-6 2-methoxy-5-cyanophenol 
• 54170-11-5 3-benzyloxy-4-methoxy-benzylamine 
• 108439-67-4 3-ethoxy-4-methoxybenzylamine 
• 192869-56-0 5-benzyloxy-4-methoxy-2-nitro-benzonitrile 

Relevant articles and documents

4-anilinoquinazoline derivative and albumin conjugates thereof

a pharmaceutical composition for preventing, treating, or ameliorating one or more symptoms of a malignant tumor associated with EGFR mutation and/or K-RAS mutation is provided. The pharmaceutical composition includes a 4-anilinoquinazoline derivative having a formula (I) where A is iodine when m is 1 and n is zero, or A is albumin when m is an integral ranging from 1 to 7 and n is 1.

Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue

A series of erlotinib analogues that have structural modification at 6,7-alkoxyl positions is efficiently synthesized. The in vitro anti-tumor activity of synthesized compounds is studied in two non-small cell lung cancer (NSCLC) cell lines (A549 and H1975). Among the synthesized compounds, the iodo compound 6 (ETN-6) exhibits higher anti-cancer activity compared to erlotinib. An efficient method is developed for the conjugation of erlotinib analogue-4, alcohol compound, with protein, bovine serum albumin (BSA), via succinic acid linker. The in vitro anti-tumor activity of the protein attached erlotinib analogue, 8 (ETN-4-Suc-BSA), showed stronger inhibitory activity in both A549 and H1975 NSCLC cell lines.

Optimization of gefitinib analogues with potent anticancer activity

The interactions of gefitinib (Iressa) in EGFR are hydrogen bonding and van der Waals forces through quinazoline and aniline rings. However the morpholino group of gefitinib is poorly ordered due to its weak electron density. A series of novel piperazino analogues of gefitinib where morpholino group substituted with various piperazino groups were designed and synthesized. Most of them indicated significant anti-cancer activities against human cancer cell lines. In particular, compounds 52-54 showed excellent potency against cancer cells. Convergent synthetic approach has been developed for the synthesis of gefitinib intermediate which can lead to gefitinib as well as numerous analogues.